Earnings Feed
Start Free
Home/Filings/4/0001062993-25-013460
4//SEC Filing

CRANDELL KEITH 4

Accession 0001062993-25-013460

CIK 0001894562other
View on SEC.govCompany Profile

Filed

Jul 31, 8:00 PM ET

Accepted

Aug 1, 7:18 PM ET

Size

20.3 KB

Accession

0001062993-25-013460

Insider Transaction Report

Form 4
Period: 2025-08-01
Prime Medicine, Inc.PRME
ARCH Venture Partners X Overage, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297
ARCH Venture Partners X, LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297
ARCH Venture Fund X, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297
ARCH Venture Partners X, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297
CRANDELL KEITH
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297
Burow Kristina
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297
GILLIS STEVEN
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297
ARCH Venture Fund X Overage, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-08-01$3.30/sh+3,030,300$9,999,990→ 6,230,300 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    6,128,297

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    6,128,297
Footnotes (4)
  • [F1]Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
  • [F2]Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
  • [F3]ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
  • [F4]Represents shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the general partner of AVP XII LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Documents

1 file

Issuer

Prime Medicine, Inc.

CIK 0001894562

→
Entity typeother

Related Parties

1
  • filerCIK 0001219039

Filing Metadata

Form type
4
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 7:18 PM ET
Size
20.3 KB
View on SEC.gov